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The eosinophil cationic protein (ECP)' is one of several small, distinct arginine-
rich proteins that have been isolated from the eosinophil's large specific granule.
Themolecularmass ofhumanECP hasbeen estimated at 18-21 kD (1-3), depending
on the degree of glycosylation (3) . ECP has been shown to possess a wide variety
of biological activities, including the ability to stimulate factor XII-dependent coagu-
lation pathways (4), to neutralize the anticoagulant effects of heparin (5), and to in-
hibit lymphocyte proliferation induced by PHA or mixed lymphocyte reactions (6) .
ECP is a potent cytotoxin ; ECP-containing supernatants of activated eosinophils
have been shown to be toxic to isolated myocardial cells in vitro (7), and both ECP
andthe eosinophil granule majorbasic protein(MBP)were found in the endothelial
and endomyocardial lesions characteristic of the hypereosinophilic syndrome (8) .
Furthermore, ECP is also a potent helminthotoxin ; destruction of schistosomula of
Schistosoma mansont was reported at concentrations as low as 10'M (8-10-fold more
active than MBP) (9, 10) . ECP has also been shown to kill trypomastigote and
amastigote stages of Trypanosoma cruzi (11) . Both ECP and the related granule pro-
tein, eosinophil-derived neurotoxin (EDN), induce the neurotoxic effect known as
the Gordon phenomenon (12) when injected into the cerebrospinal fluid of ex-
perimental animals (3, 13-15) . Although the molecular mechanism(s) by which ECP
carries out these varied biologic activities is not clear, Young et al. (16) have sug-
gested thatECP might damage cells by a colloid-osmotic process, as they have shown
that it can introduce non-ion selective pores in both cellular and synthetic membranes .
Gleich et al . (3) published the NH2-terminal sequences of ECP and the related
granule protein, EDN ; the NH2-terminal sequence of ECP showed 67% identity
to that ofEDN, and 26% identity to the sequence ofhuman pancreatic ribonuclease
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(HPR), suggesting that ECP and EDN might belong to the ribonuclease multigene
family. ECP and EDN were subsequently found to have ribonuclease activity, with
ECP showing 100-fold less activity than EDN against a yeast RNA substrate (17,
18). We have previously isolated and sequenced a full-length cDNA clone for EDN
(19); the complete cDNA-derived amino acid sequence was identical to a human
nonsecretory ribonuclease isolated from urine (HNSR) (19, 20). In addition, there
was 32 % sequence identity between EDN and HPR, including conservation of the
structural cysteine and catalytic lysine and histidine residues. We now report the
isolation of a full-length cDNA clone for ECP The predicted amino acid sequence
of mature ECP shows 66% sequence identity with EDN/HNSR, but has 12 more
arginine residues and a higher net positive charge. While EDN is expressed in a
wide variety of hematopoietic cells and cell lines (19), ECP appears to be expressed
only in eosinophils and their precursors.
Materials and Methods
Purification of RNAfrom Peripheral Blood Cells.
￿
Peripheral blood granulocytes obtained by
leukapheresis of a patient with the hypereosinophilic syndrome were purified as described
(19). After two washes in cold HBSS and lysis ofRBC by briefsuspensionin cold lysis buffer
(100 mM potassium carbonate, 150 mM ammonium chloride, and 0.1 mM EDTA, pH 7.2),
the resuspended cell pellet was underlayered with a cushion of Ficoll-Hypaque (1.077 g/ml;
Pharmacia Fine Chemicals, Piscataway, NJ) and centrifuged at 400 g for 30 min at room
temperature. The mature granulocytes in the pellet were separated from cells suspended in
the Ficoll-Hypaque layer(hypodense granulocytes and some mononuclear cells), and the RNA
was extracted and purified by guanidium-isothiocyanate extraction followed by cesium chlo-
ride density gradient centrifugation (21). RNA from discarded samples ofnormal bone marrow
cells was purified as described except without cell separation over Ficoll-Hypaque. Mono-
cytes were purified from peripheral blood of normal donors by Ficoll-Hypaque density cen-
trifugation and adherence to plastic. Neutrophil RNA was purified from peripheral blood
neutrophils obtained from normal donors. Cells were washed and separated over Ficoll-
Hypaque as above; in each case, the pellets contained <5% contaminating eosinophils.
cDNA Library Screening.
￿
cDNA clones for ECP were isolated from a X gtll library pre-
pared from poly (A)' RNA purified from the peripheral mononuclear cells of a patient with
eosinophilic leukemia, and from a A gt11 library obtained from Dr. Stuart Orkin (Children's
Hospital Medical Center, Boston, MA) prepared from poly (A)' RNA from HL-60 cells in-
duced for 7 d with DMSO. Screening was done with a 17-base 32-fold degenerate oligonucle-
otide (Fig. 1) synthesized on a DNA synthesizer (model 381; ABI, Foster City, CA) and radio-
labeled on the 5' end using y[32P]ATP (New England Nuclear, Boston, MA) and T4
polynucleotide kinase (22) or on the 3' end with a threefold molarexcess ofa[32p]dCTP (New
England Nuclear) and terminal deoxynucleotidyl transferase (International Biotechnologies,
Inc., New Haven, CT). Prehybridization, hybridization, and washing were done as described
(23), except for the washing procedure, which included two washes at room temperature in
6 x SSC (22) followed by a 1-min final wash in 6 x SSC at 37°C. Positive recombinants were
purified and the inserts subcloned into M13 phage for dideoxy nucleotide sequencing (24).
Sequence evaluation was done with the assistance of Bionet (Menlo Park, CA) and DNAstar
(Madison, WI) sequence analysis software.
Induction ofHL-60Differentiation.
￿
RNA was extracted as described above from cells of the
promyelocytic leukemia HL-60 cell line (American Type Culture Collection no. CCL-240)
grown in RPMI 1640 medium supplemented with 10% FCS (Gibco Laboratories, Grand
Island, NY) both with and without inducing agents, which included 48 h in 5 x 10-7 M
vitamin D3 or 48 h in 1.1% DMSO. The monocytic or granulocytic induction of HL-60 cells
was verified by morphology as well as mRNA and surface expression ofCDllb, as previously
described (25). RNA was also extracted from a cloned subline of HL-60 committed to eo-
sinophilic differentiation (HL-60 3 + c - 5 [26]) grown either in the absence of inducing
agents or in the presence of 10°Io BCGR2/IL-5 (CellularProducts, Inc., Buffalo, NY) for 72 h.ROSENBERG ET AL.
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Northern Blotting andHybridization.
￿
Total RNA samples (10,ug each), extracted and purified
as described above, were analyzed by agarose formaldehyde gel electrophoresis, ethidium
stained to ensure equivalent RNA loading, and blotted onto nylon membranes (ICN Bio-
medicals, Irvine, CA) in 10x SSC (22). The ECP (bases 1-725) and EDN (bases 171-725)
cDNA probes were labeled with a[32p]dCTP by the random hexamer priming method (27).
Filters were prehybridized for at least 4 h in a solution containing 5x SSC, 50 % formamide,
5 x Denhardt's solution, 0.05 M sodium phosphate, pH 6.5, 1% glycine, 0.1% SDS, and 250gg/
Etl sheared denatured salmon sperm DNA at 42°C . Hybridization was done in a solution
containing 50% formamide, 5x SSC, 1 x Denhardt's solution, 0.02 M sodium phosphate,
pH 6.5, and 106 cpm/ml denatured radiolabeled probe at 42 °C for at least 12 h (22). Hy-
bridized filters were washed twice at room temperature in 2x SSC, and for 30 min at 55°C
in 0.2 x SSC; washed filters were exposed for 48 h to Kodak XAR film with a single inten-
sifying screen at -80°C. RNA size standards (0.16-1.77 kb) were purchased from Bethesda
Research Laboratories, Gaithersburg, MD.
Results
Isolation andSequencing ofcDNA Clones.
￿
Primary screening of the eosinophil leukemia
X gtll cDNA library with the 32-fold degenerate oligonucleotide no. 73 (Fig. 1) yielded
a 483-bp cDNA clone (nucleotides 243-725). Subsequent screening of this library
with this cDNA probe yielded a longer clone (nucleotides 192-725); the full-length
(725 bp) cDNA clone was isolated from the DMSO-induced HL-60 X gtll cDNA
library. Fig. 1 shows the nucleotide sequence ofthe cDNA for ECP; both the coding
and noncoding strands were sequenced to completion. The complete cDNA clone
contains a Kozak-like translation initiation sequence at nucleotides 52-58 (28), an
open reading frame extending from nucleotides 55-534 (encoding a total of 160 amino
acids), and a polyadenylation signal at nucleotides 695-700, with a 15-base spacer
preceding the poly A tail. The nucleotide sequence of the cDNA clone for ECP is
89% identical to that reported for the related eosinophil granule protein, EDN (19).
There are a total of 81 by mismatches (including a single three-base gap at nucleo-
tides 487-489), with 72 ofthe mismatches found within the coding region; 62 (86%)
of the mismatches within the coding region result in changes in the encoded amino
acid sequence.
The amino acid sequence encoded by the ECP cDNA confirms the identity of
the 60 residues previously identified by NH2-terminal sequencing (3). The NH2-
terminal arginine residue of granule-extracted ECP is the arginine encoded by nucleo-
tides 136-138; the molecular mass ofthe protein encoded from nucleotides 136-534
is 15 .6 kD. The amino acid sequence contains three Asn-XThr/Ser sequences that
have been identified as sites of potential N-linked glycosylation (29-31).
From nucleotides 55 to 135, the open reading frame encodes a 27-residue segment
that was not previously identified in the NH2-terminal sequence of granule-derived
ECP (3). This segment is markedly hydrophobic; 20 of the 27 residues are either
hydrophobic or aliphatic. A 27-residue NH2-terminal hydrophobic sequence was
also encoded by the cDNA isolated for EDN (19); 24 of the 27 NH2-terminal
residues of this ECP leader sequence are identical to those of EDN.
Sequence Comparisons.
￿
Fig. 2 a shows the alignment of the cDNA-derived amino
acid sequences of mature ECP and EDN, without the aforementioned NH2-termi-
nal hydrophobic sequences. Ofthe 133 amino acids encoded by ECP cDNA, 88 have
identical counterparts in the sequence of EDN (thus, 66% identity between the two
sequences). Despite the similarities in amino acid sequence, the calculated isoelec-
tric points of the two peptides differ significantly; the calculated pI of ECP is 10.8,166
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FIGURE 1.
￿
Nucleotide sequence of the 725-base coding strand of the ECP cDNA with transla-
tion ofthe open readingframe (160 aminoacids), potential N-linked glycosylation sites(under-
lined), and location of the 32-fold degenerate (no. 73) 17-base oligonucleotide probeused to iso-
late the cDNA. The Kozak initiation sequence containing the presumptive start codon (ATG)
at nucleotides 52-58 is boxed, the NH2 terminus (R, position +1) of the granule-derived pro-
tein is boxed anddarkly shaded, andthe stop codon (TAA) at nucleotides 535-537 is boxed and
lightlyshaded. The 3' polyadenylation signal (AATAAA) at nucleotides 695-700is boldly under-
lined. The 27-amino acid leader sequence precedes the NH2-terminal R, and is denoted as po-
sitions -27to -1. Thesesequence data have been submittedto the EMBL/GenBank Data Libraries
under the accession number X15161.
C T I A M R A 1 N N Y R W R C K
#73
38
AC CAA AAT ACT TTT CTT CGT ACA ACT TTT GCT AAT GTA GTT AAT GTT TGT 300
N 0 N T F L R T T F A N V V N V C 55
GGT AAC CAA AGT ATA CGC TGC COT CAT AAC AGA ACT CTC AAC AAT TGT CA 350
G N 0 S I R C P H N R T L N N C H 72
TCGGAGTAGATTCCGGGTGCOTTTAOTCCACTGTGACCTCATAAATCCAG 400
R S R F R V P L L H C D L I N P 88
GT GCA CAG AAT ATT TCA AAC TGC AGG TAT GCA GAC AGA CCA GGA AGG AGG 450
G A 0 N I S N C R Y A D R P G R R 105
TTC TAT GTA GTT GCA TGT GAC AAC AGA GAT CCA CGG GAT TOT CCA CGG TA 500
F Y V V A C D N R D P R D S P R Y 122
T COT GTG GTT CCA GTT CAC CTG GAT ACC ACC ATC GOT OCT GTA TCA G 550
P V V P V H L D T T I 133
CA GTC OTC ATC ATC ACT CAT CTG CCA AGO TOO TCA ATC ATA GOO AAG ATC 600
CCA TOO CTC CAT GTA CTC TGG GTA TCA GCA ACT GTC CTC ATC AGT CTC CA 650
T ACC OCT TO A GOT TTC CTG AGO TGA AGT COO TTG TGA ACC CTG CAA TAA A 700
CT G CT TTG CAA ATT CAA AAA AAA AA 725
GAACAACCAGCTGGATCAGTTCTCACAGGAGCCACAGOTCAGAGACTGGG 50
AAC ATG TT CCA AAA CTG TTC ACT TOO CAA ATT TGT CTG OTT CTT CTG T 100
M V P K L F T S 0 I C L L L L -13
TG GGG CTT ATG GGT GTG GAG GGC TCA CTC CAT
Gee
AGA COO CCA CAG TTT 150
L G L M G V E G S L H A P P 0 F 5
ACG AGG GOT CAG TGG TTT GOO ATC CAG CAC ATC AGT CTG AAC COO COT CG 200
T R A 0 W F A I 0 H I S L N P P R 22
A TGC ACC ATT GCA ATG CGG GCA ATT AAC AAT TAT CGA TGG CGT TGC AAA A 250ROSENBERG ET AL .
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(a) Alignment of the cDNA-derived amino acid sequences ofECP and EDN (not
including leader sequences) . Regions ofidentical sequence are within the boxes ; the cysteine residues
are within the shaded boxes. All arginine residues (R) in ECP have been circled (total of 20) ;
arginine residues present in ECP but not in EDN have also been shaded. Numbering is as per
theECPsequence . (b) Alignment oftheamino acid sequences of ECP, EDN (identical to HNSR
[19, 20]), HLR(32), HPR (33), and ANG (34, 35) . Regions ofconserved sequence are enclosed
in boxes, conserved cysteine residues are lightly shaded, and the putative catalytic histidine and
lysine residues are heavily shaded . Dashes represent gaps introduced to permit alignment of cys-
teines and ofthe catalytic residues . Numbers aboveand to the right are as per the sequence ofECP
167168
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while that of EDN is 8.9 . The higher calculated pI reflects ECP's higher arginine
content . While EDN has eight arginine residues, ECP has a total of 20 arginine
residues ; at 15 of the 45 residues (33%) at which ECP and EDN differ, there is an
arginine residue in the ECP sequence.
Fig. 2 b shows the alignment of the cDNA-derived amino acid sequence of ECP
(beginning at the arginine at position 1 of the NH2 terminus of the granule-
extracted protein [3]) with thesequences ofEDN(19) (shown to be identical toHNSR
[19, 20]), human liver ribonuclease (HLR) (32), HPR (33), and angiogenin (ANG)
(34, 35) . The sequences of EDN, HNSR, and the 25 NH2-terminal residues of
HLR are identical. While the sequence of ECP shows 66% identity with the se-
quences of EDN (and thus HNSR and HLR), there is only 31% identity between
ECP and HPR, and 25% identity between ECP and ANG.
Northern Analysis.
￿
Thepresence ofmRNA encoding ECP wasassessed in a number
of hematopoietic cells and cell lines . Fig . 3 shows a Northern analysis of various
FIGURE 3 . Northern analysis
ofmRNA forECP. Blots oftotal
RNA (10 kg) from hematopoi-
etic cells and cell lines were
probed with the 725-bp full-
lengthcDNA for ECP (a and c)
and reprobed after the ECP
signal had decayed with a 554-
bp cDNA for EDN (19) (b and
d) . HL-60 (American Type Cul-
ture Collection no. CCL-240)
cells grown in the absence ofin-
ducing agents (a and b, lane 1);
HL-60 cells grown for 48 h with
5 x 10-7 M vitamin D3 (a and
b, lane 2) ; or for 48 h with 1 .1%
DMSO (a and b, lane 3) ; pe-
ripheral blood monocytes (a and
b, lane 4); cloned HL-60 sub-
line committed to eosinophilic
differentiation, HL-60 3 + c - 5
(26) grown in the absence ofin-
ducing agents (c and d, lane 1) or
for 72 h with 10% BCGF2/IL-5
(c and d, lane 2) ; hypodense leu-
kocytes (density approximately
1.077 g/ml) from a patient with
the hypereosinophilic syndrome
(68% eosinophils, 30% neutro-
phils, 2% mononuclear cells) (c
and d, lane 3) ; more normal
density (>1.077 g/ml) granulo-
cytes from a patient with the hy-
pereosinophilic syndrome (73
eosinophils and 27% neutro-
phils) (c and d, lane 4); human
bone marrow cells(c and d, lane
5). 28S and 18S refer to themo-
bilities of the ribosomal RNA
bands visualized by ethidium
staining ; equivalent intensity
was observed in all lanes .ROSENBERG ET AL.
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sources ofRNA probed with the 725-bp cDNA for ECP and a 554-bp cDNA for
EDN (19). The molecular sizes ofthe ECP and EDN mRNAs were indistinguish-
able on the basis of their electrophoretic mobilities; comparison with RNA stan-
dards gave an estimate ofthemolecular size as 970 bases, which is compatible with
a short 5' untranslated region and 3' poly A tail. Whereas mRNA for EDN was de-
tected in uninduced cellsofthepromyelocytic line, HL-60 (Fig. 3 b, lane 1), mRNA
for ECP was either absent or present at levels below detectable limits in these cells
(Fig. 3 a, lane 1 and Fig. 3 c, lane 1). Likewise, mRNA for ECP was not detected
in HL-60 cells induced toward monocytic differentiation with vitamin D3 (Fig. 3
a, lane 2), or in mature monocytes (Fig. 3 a, lane 4).
In contrast, mRNA for EDN was detected in vitamin D3-induced HL-60 cells
(Fig. 3 b, lane 2) and in mature peripheral monocytes (Fig. 3 b, lane 4), but at
significantly lower levels than in the uninduced HL-60 cells. Despite the fact that
ECP mRNA was undetectable in the uninduced HL-60 eosinophilic subline (Fig.
3 c, lane 1), there was ECP mRNA detected in cells induced toward eosinophilic
differentiation with BCGF2/IL-5 (Fig. 3 c, lane 2); EDN mRNA was likewise up-
regulated with this induction (Fig. 3 d, lane 2). There was also an up-regulation
of EDN mRNA in HL-60 cells induced toward neutrophilic differentiation with
DMSO (Fig. 3 b, lane3); in contrast, mRNA forECP remained undetectable under
these conditions (Fig. 3 a, lane 3), and was not detectable in mRNA from mature
neutrophils(notshown). mRNAforboth ECP and EDN was detected in total RNA
samples prepared from Ficoll-Hypaque fractions of hypodense peripheral blood
eosinophil-rich granulocytes (68% eosinophils, 30% neutrophils, 2% mononuclear
cells) (Fig. 3 c, lane 3 and Fig. 3 d, lane 3) or from peripheral blood eosinophil-rich
granulocytes of normal density (73% eosinophils, 27% neutrophils) (Fig. 3 c, lane
4 and Fig. 3 d, lane 4), both obtained from a patient with the hypereosinophilic
syndrome. Neither message was detected in the sample of total RNA from bone
marrow cells (Fig. 3 c, lane 5 and Fig. 3 d, lane 5).
Discussion
ECP and EDN are cationic granule proteins with similar amino acid content (5,
36, 37) that are distinguishable onthe basis ofmolecularsize, immunogenicity, and
biological activities (37). We have isolated full-length cDNA clones for both EDN
(19) andECP The cDNA sequences ofECP andEDN are 89% identical; the Kozak-
like translation initiation sequences, stop codon (TAA), and location ofthe polyade-
nylation signal (AATAAA) with respect to the polyA tail are the same inboth cDNA
sequences.
The cDNA sequence of ECP encodes a 160-amino acid polypeptide, one fewer
than the cDNA for EDN, which encodes 161 amino acids (19). Alignment of both
the cDNA andthe amino acid sequences placed the gap at codonCGA (nucleotides
475-477 ofthe EDN cDNA) correspondingto the omission in ECP ofarginine 118
in EDN. This arginine is not a putative catalytic residue, nor is it conserved among
ribonucleases in general (38); its significance with respect to the functional differ-
ences between EDN and ECP is unknown.
The 27 NH2-terminal residues encoded by the ECP cDNA are not found in the
NH2-terminal sequence of the granule-extracted protein (3). This segment is
markedly hydrophobic, with a sequence of 10 uninterrupted hydrophobic/aliphatic170
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residues, characteristic of a leader sequence (39, 40). The alanine at position -1
andleucine at position -3 are consistent with von Heijne's criteria for signal pepti-
dase cleavage (41). The process (biosynthesis, packaging into granules, or degranu-
lation/secretion) during which the hydrophobic leader sequence is removed from
ECP (or EDN) is not known. In the case of ECP, there is some evidence to suggest
that the leader sequence may persist to the secretion stage. Tai et al. (42) have de-
scribed mAbs that can distinguish between storage (granule) and secreted forms of
ECP; monoclonal EG-1 interactswith both storage and secreted ECP, whereas EG-
2 recognizes only the secreted form. Interestingly, ECP extracted directly from iso-
lated granules is immunologically indistinguishable from the secreted form (recog-
nized by both EG-1 and EG-2) and has no leader sequence (3). It is conceivable
that the leader sequence is cleaved during secretion (or extraction). This cleavage
could result in either a local conformational change and/or exposure of apreviously
masked epitopepermitting recognitionby the monoclonal EG-2 . Alternatively, EG-
2 might simply recognize an epitope that is masked while ECP is packaged in the
granule, unrelated to the presence or absence of a leader sequence.
The sequence similarities reported by Gleich et al. (3) for the N112-terminal
residues of granule-extracted ECP and EDN also extend through the COON ter-
mini of thepolypeptide sequences (Fig. 2 a). Themature ECP polypeptide(without
leader sequence) contains 133 amino acids, which is one fewer than that found in
EDN (discussed above), with a sequence similarity between the two polypeptides
of 66%. The calculated molecular mass of mature ECP is 15 .6 kD, which is slightly
higher than that of EDN(15.5 kD). Despitethesequence similarities, there is astriking
difference in their net charges (pI of ECP is 10 .8 vs. 8.9 for EDN). The arginine
content of ECP is markedly higher than that of EDN (20 arginine residues in ECP
and only eight in EDN). It is possible that this high positive charge confers on ECP
the cytotoxic and helminthotoxic properties that are lacking in EDN. Young et al.
(16) have shown that ECP (but not eosinophil protein X, which may be identical
to EDN [37, Gleich, G. J., personal communication]) has perforin-like activity. In
their experiments, ECP induced hemolysis and introduced non-ion-selective pores
in both cellular andsyntheticlipid membranes. By analogy, mellitin, the major com-
ponent of honeybee venom, is a 26-amino acid cationic polypeptide that also in-
teractswith cell membranes and results in cell lysis (43). It is not clearwhether mel-
litin introduces ion pores (44, 45) or disrupts the hydrophobic bonding of the
phospholipid bilayer(46, 47). DeGrado et al. (46) have shown that when thecationic
component of mellitin, the C0011-terminal hexapeptide (sequence KRKRQQ),
is removed, the remaining polypeptide remains capable of binding to erythrocyte
membranes, but there is no cell lysis. Mellitin-mediated cell lysis is clearly depen-
dent on the presence of ahighly positively charged segment; the positively charged
residues present in the sequence of ECP (but not EDN) might be responsible for
ECP's cytotoxic properties.
Gleich et al. (3) noted the sequences similarities between ECP, EDN, and theamino
acid sequence of HPR, and suggestedthat this group comprised amultigene family.
HPR belongs to the secretorygroup ofmammalian ribonucleases, which are charac-
terizedby alkaline pH optima and immunological crossreactivity(48), andhave also
been found in kidney, stomach, and saliva (49-53). This group is immunologicallyROSENBERG ET AL.
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distinct from the neutral, nonsecretory ribonucleases, which have pH optima near
6.5, and have been found in spleen, lung, liver, and leukocytes (49, 50, 53, 54). We
have previously shown that EDN is identical toanonsecretory ribonuclease isolated
from human urine (HNSR) (19, 20) and to the known 25 NH2-terminal residues
of HLR (32); our previous results also suggested that EDN may have an identical
counterpart in neutrophils (19). ECP is clearly more closely related to these non-
secretory ribonucleases than it is to human pancreatic ribonuclease. In addition,
ECP shows 25% sequence identity to ANG, a small polypeptide isolated initially
from adenocarcinoma cells (55), that has both angiogenic and ribonucleolytic ac-
tivities (55-57) and an amino acid sequence similar to other members ofthe ribo-
nuclease multigene family (34, 35).
We previously reported that the complete sequences ofEDN, HNSR, and HPR
showed conservation ofall eight cysteine residues andthe putative catalytic histidine
andlysine residues characteristic ofother ribonucleases (19). The complete sequence
of ECP, likewise, contains these same features. Slifman et al. (17) have shown that
both EDN and ECP have ribonuclease activity. While the ribonucleolytic activity
ofEDN is equivalent to that ofRNase A, ECP was found to be 100-fold less active
against the yeast RNA substrate. We have repeated these experiments with a yeast
tRNA substrate, with identical results (Corrette, S. E. and S. J. Ackerman, unpub-
lished observations). AsECPcontains both the structurallyimportantcysteineresidues,
as well asthe catalytic histidines and lysine (Fig. 2 b), there should be another expla-
nation for its reduced ribonucleolytic activity. One significant difference between
the primary structures ofECP and EDN is, as described above, the highly positive
charge ofECP The electrostatic charge between the positively charged ECP and
negatively charged RNA might prevent the substrate from binding in an appro-
priate conformation in the catalytic site, or may inhibit turnover by hindering re-
lease ofthenegatively charged cleaved products. Angiogenin was also characterized
as apoor ribonuclease when tested against standard RNA substrates (56). However,
St. Clair et al. (57) have reported that angiogenin effectively abolishes in vitro pro-
tein synthesis by specific cleavage of 28S and 18S rRNA; ECP may have a similar
substrate specificity.
MBP is a distinct eosinophil cationicprotein (molecular massof 13.9 kD [58, 59])
that comprises theelectron-dense crystalloid core ofthe eosinophils' specific granule
(37). ECP and MBPhave similarfunctions; both ECPand MBP damage schistoso-
mula ofS. mansoni (9, 10), neutralize heparin (5, 37), and are implicated as medi-
ators ofthe myocardial, endothelial, and endocardial damage (8), characteristic of
prolonged hypereosinophilicstates suchas the idiopathic hypereosinophilic syndrome
(60). Despite these shared activities, the amino acid sequences of ECP and MBP
(58, 59) show only insignificant sequence similarity (5%), making a common mo-
lecular mechanism ofaction unlikely. Some activities are clearly not shared; MBP,
but not ECP, induces noncytolytic histaminerelease from human basophils (61, 62).
Furthermore, the effectivenessofECP and MBP against schistosomula ofS mansoni
differed on both quantitative and qualitative bases. Whereas ECP killed 100% of
schistosomula in vitro at a 3.75 x 10-6 M concentration, MBP at this concentra-
tion was only marginally toxic, killing only 15% (10). Also, MBP resulted in bal-
looning ofthe schistosomulategumental membrane, while ECP caused amore com-172
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plete fragmentation (10). Asthe molecular mechanisms by whichthese two proteins
function are likely to bedifferent, their helminthotoxic and cytotoxic activities may
be synergistic.
ECP mRNA and EDN mRNA areindistinguishableonthebasis ofelectrophoretic
mobility. Despite size and sequence similarities, there is clearly differential regula-
tionofthe twomRNA species. EDN mRNAwas detectable inuninducedpromyelo-
cyticleukemia HL-60 cells, and was clearlyup-regulated with induction toward eo-
sinophilic (BCGF2/IL-5) and, as previously reported (19), toward neutrophilic
(DMSO) differentiation. In contrast, ECP mRNA was seen only in an eosinophil-
committed subline of HL-60 cells induced toward eosinophilic differentiation and
ineosinophil-richpreparations ofperipheral granulocytes. ECP mRNA wasnot present
in HL-60cellsinduced toward neutrophilic (DMSO)differentiation, norwas it present
in peripheral blood neutrophils. In support of these findings, induction of HL-60
cells with DMSO leads to a diminution ofother eosinophil-specific characteristics,
includinga decrease in Biebrich scarletstaining (63, 64), and reduced mRNA tran-
scription for (65) and biosynthesis of MBP (63).
In summary, mRNA forECPwas presentonly in eosinophil-rich granulocyte prepa-
rations and HL-60 cells induced toward eosinophilic differentiation; unlike EDN,
ECP appears to be an eosinophil-specific protein. These results suggest that ECP
and EDN may be subject to different regulatory mechanisms. We hypothesize that
ECP may have arisen from the ubiquitous EDN ribonuclease as a gene duplication
event, and subsequently acquired mutations (i.e., the substitution ofmultiple argi-
nine residues) mayhave tailored ECP to subserve eosinophil-specific helminthotoxic
and cytotoxic activities. We are currently attempting to isolate genomic clones for
both ECP and EDN, with the hope of identifying discrete sequences responsible
for the observed differential regulation of transcription.
Summary
We have isolated a 725-bp full-length cDNA clone for the human eosinophil cat-
ionic protein (ECP). ECP is a small, basic protein found in the matrix of the eo-
sinophil's large specific granulethat hascytotoxic, helminthotoxic, andribonuclease
activity, andis amemberofthe ribonuclease multipene family. ThecDNA sequence
shows 89% sequence identity with that reported for the related granule protein,
eosinophil-derived neurotoxin (EDN). Theopen readingframeencodesapreviously
unidentified 27-amino acid leader sequence preceding a 133-residue mature ECP
polypeptide with a molecular mass of 15.6 kD. The encoded amino acid sequence
ofECP shows 66% identity to that ofEDN and 31% identity to that ofhuman pan-
creatic ribonuclease, including conservation ofthe essential structural cysteine and
catalytic lysine and histidine residues. mRNA for ECP was detected in eosinophil-
enriched peripheral granulocytes and in a subclone of the promyelocytic leukemia
line, HL-60, inducedtoward eosinophilicdifferentiation with IL-5. No ECP mRNA
wasdetected inuninduced HL-60cells, orin HL-60 cells inducedtoward monocytic
differentiation withvitamin D3 ortoward neutrophilic differentiationwith DMSO.
In contrast, mRNA for EDN was detected in uninduced HL-60 cells and was up-
regulated in HL-60 cells induced with DMSO. Despite similarities in sequence and
cellular localization, these results suggestthat ECP and EDN are subject todifferent
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